Drug intelligence / Profile preview

ACC006

Development stage: Phase 2
Lead developer: AIDEA PHARMA
Modality: Small Molecules
Administration: Oral

Overview

ACC006 is an orally administered small molecule drug under development primarily for the treatment of squamous non-small cell lung cancer (NSCLC). It acts as an inhibitor of the mechanistic target of rapamycin (mTOR), a key regulator in cell growth and proliferation pathways. The drug has been studied both as monotherapy and in combination with other agents such as tislelizumab (a PD-1 inhibitor) and with albumin-bound paclitaxel plus carboplatin, targeting advanced or recurrent/metastatic NSCLC. Development is led by Jiangsu Aidea Pharmaceutical, with clinical trials conducted in China[1][2][3][5][9].

Targets

SHH (Sonic hedgehog)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on ACC006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACC006.